Oramed Pharmaceuticals Inc has a consensus price target of $16.4, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from Canaccord Genuity, HC Wainwright & Co., and Canaccord Genuity on May 17, 2023, January 17, 2023, and January 12, 2023. With an average price target of $0.67 between Canaccord Genuity, HC Wainwright & Co., and Canaccord Genuity, there's an implied -73.01% downside for Oramed Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
05/17/2023 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.47 | -19.03% | Canaccord Genuity | Edward Nash | $3 → $2 | Maintains | Hold | Get Alert |
01/17/2023 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.47 | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Downgrade | Buy → Neutral | Get Alert |
01/12/2023 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.47 | — | Canaccord Genuity | Edward Nash | — | Downgrade | Buy → Hold | Get Alert |
05/16/2022 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.47 | 1114.57% | Aegis Capital | Nathan Weinstein | $35 → $30 | Maintains | Buy | Get Alert |
02/18/2022 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.47 | 709.72% | Cantor Fitzgerald | Charles Duncan | → $20 | Initiates | → Overweight | Get Alert |
11/30/2021 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.47 | 1195.55% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
11/29/2021 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.47 | 1195.55% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
11/02/2021 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.47 | 1317% | Aegis Capital | Nathan Weinstein | — | Maintains | Buy | Get Alert |
07/29/2021 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.47 | 1114.57% | Canaccord Genuity | — | — | Maintains | Buy | Get Alert |
06/08/2021 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.47 | 709.72% | Aegis Capital | Nathan Weinstein | — | Maintains | Buy | Get Alert |
The latest price target for Oramed Pharmaceuticals (NASDAQ: ORMP) was reported by Canaccord Genuity on May 17, 2023. The analyst firm set a price target for $2.00 expecting ORMP to fall to within 12 months (a possible -19.03% downside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Oramed Pharmaceuticals (NASDAQ: ORMP) was provided by Canaccord Genuity, and Oramed Pharmaceuticals maintained their hold rating.
There is no last upgrade for Oramed Pharmaceuticals.
The last downgrade for Oramed Pharmaceuticals Inc happened on January 17, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Oramed Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oramed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oramed Pharmaceuticals was filed on May 17, 2023 so you should expect the next rating to be made available sometime around May 17, 2024.
While ratings are subjective and will change, the latest Oramed Pharmaceuticals (ORMP) rating was a maintained with a price target of $3.00 to $2.00. The current price Oramed Pharmaceuticals (ORMP) is trading at is $2.47, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.